COR2ED The Heart of Medical Education
COR2ED The Heart of Medical Education
  • Видео 181
  • Просмотров 602 547
Precision oncology in prostate cancer: tips for optimal genomic testing
Have you ever wondered if you're getting the most out of genomic testing for prostate cancer?
In this animated video, GU cancer genomics expert Dr Alexander Wyatt shares the guideline recommendations and best tips for precision oncology in prostate cancer.
Multi-gene germline and somatic testing is required for the identification of gene alterations in advanced prostate cancer. Both tissue and liquid biopsy (ctDNA) can be used for somatic testing, but it’s important for HCPs to know when to use liquid biopsy and how to conserve the quality of tissue samples.
Dr Wyatt addresses these questions and highlights other key points, including:
- Common genomic alterations and implications in pros...
Просмотров: 94

Видео

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape
Просмотров 69День назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this episode the experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions. Prefer to listen on the...
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
Просмотров 45День назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this episode the experts deep-dive into two patient case studies of ER /HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusti...
Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges
Просмотров 73День назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this final episode of this podcast the experts discuss the next two patient case studies of ER /HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professi...
Update from ESMO 2024: Immunotherapy (IO) for HCC
Просмотров 24 тыс.День назад
In this video update, Dr Richard S. Finn shares his perspective on the latest hepatocellular carcinoma (HCC) data on immunotherapy (IO) and IO-based treatments to emerge from ESMO 2024. Dr Finn reviews data from the following clinical trials: - HIMALAYA - CheckMate 9DW - LEAP-012 - IMbrave050 Download the accompanying slides from the COR2ED website: cor2ed.com/n-connect/programmes/esmo-2024-lun...
Oncogene-addicted NSCLC update from WCLC and ESMO 2024
Просмотров 31 тыс.14 дней назад
In this video update, Dr Herbert H. Loong shares his perspective on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) to emerge from two important congresses, WCLC and ESMO 2024. Dr Loong reviews data from the following clinical trials (with corresponding video time stamps): 0:13 - TRUST-II 0:54 - LOXO-RAS-20001 1:47 - DESTINY-Lung03 3:02 - SOHO-01 & Beamion LUNG-1 4:07 - ...
ESMO 2024: Update on BRAF-altered lung cancer data
Просмотров 3,5 тыс.14 дней назад
Prof. Planchard and Dr Cappuzzo share their views on the latest data on BRAF-altered lung cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the following NSCLC trials: - PHAROS - IFCT-1904 ENCO-BRAF - 1L IO vs BRAF and MEK inhibitors - MoST Professors Stintzing and Dummer discuss BRAF-altered colorectal an...
ESMO 2024: Lower GI cancer update
Просмотров 2,1 тыс.14 дней назад
Prof. Chiara Cremolini and Prof. Hans Prenen share their views on the practice-changing data on lower GI cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the latest clinical trials on colorectal and rectal cancer. Dr. Sam Klempner and Dr. Lizzy Smyth discuss the upper GI cancer highlights from the meeting...
GU oncology update from ESMO 2024
Просмотров 13 тыс.14 дней назад
Dr Ray Manneh Kopp shares his views on the latest data on GU cancers presented at the ESMO 2024 congress. Watch as he reveals what he considers to be the key clinical takeaways from the following GU cancer trials: NIAGARA EORTC-GUCG 1333/PEACE-3 TiNivio-2 COR2ED brings together a selection of top experts across many tumour types, presenting their thoughts and insights on the most recent data to...
ESMO 2024: BRAF-altered colorectal and other cancers
Просмотров 20 тыс.14 дней назад
Prof. Sebastian Stintzing and Prof. Reinhard Dummer share their views on the latest data on BRAF-altered colorectal and other cancers presented at the ESMO 2024 congress. Watch the experts reveal what they consider to be the key clinical takeaways from the latest data presented on BRAF-altered colorectal cancer, brain cancer, melanoma and solid tumours. Prof. David Planchard and Dr Federico Cap...
Update from ESMO 24: Breast cancer
Просмотров 14 тыс.14 дней назад
Prof. François-Clément Bidard shares his views on the latest breast cancer data presented at the ESMO 2024 congress. Watch as he reveals what he considers to be the key the clinical takeaways from the latest results shared from the following breast cancer trials: KEYNOTE-522 DESTINYBreast-12 NATALEE COR2ED brings together a selection of top experts across many tumour types, presenting their tho...
ESMO 2024: Upper GI cancer update
Просмотров 2,4 тыс.14 дней назад
Dr Lizzy Smyth and Dr Sam Klempner share their views on the practice-changing data on upper GI cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the latest clinical trials on gastric and gastroesophageal cancer. Prof. Hans Prenen and Prof. Chiara Cremolini discuss the lower GI cancer highlights from the me...
Neuroendocrine tumours (NETs) - Shared decision-making. Episode 1: Patient journey
Просмотров 10921 день назад
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, their goals and concerns. The speakers share their real-life experience...
Highlights: NET Shared decision making - optimising physician and patient consultations
Просмотров 6921 день назад
Neuroendocrine tumours (NETs) are complex, rare diseases. Optimal management and treatment require early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision-making? Or the recent data on how patients prefer to receive treatment? Gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore in a two part...
Neuroendocrine tumours (NETs)-Shared decision-making. Episode 2: Individualising treatment decisions
Просмотров 9521 день назад
In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making between patient and physician. They discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no ...
Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM
Просмотров 11421 день назад
Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM
Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA
Просмотров 1,3 тыс.21 день назад
Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA
Multiple Myeloma: Unmet medical needs in early relapse
Просмотров 2,8 тыс.21 день назад
Multiple Myeloma: Unmet medical needs in early relapse
Update from ASCO GI 2023 Upper GI cancer highlights podcast (SHORT)
Просмотров 67Месяц назад
Update from ASCO GI 2023 Upper GI cancer highlights podcast (SHORT)
Tools for optimising treatment & management of advanced NETs
Просмотров 15 тыс.2 месяца назад
Tools for optimising treatment & management of advanced NETs
The evolving role of liquid biopsy
Просмотров 58 тыс.2 месяца назад
The evolving role of liquid biopsy
Highlights: Precision oncology in practice- testing through to treatment in lung and prostate cancer
Просмотров 833 месяца назад
Highlights: Precision oncology in practice- testing through to treatment in lung and prostate cancer
Advanced renal cell carcinoma: Managing long term durable response
Просмотров 20 тыс.3 месяца назад
Advanced renal cell carcinoma: Managing long term durable response
Advanced HCC: Treatment options for patients ineligible for IO - patient case video
Просмотров 693 месяца назад
Advanced HCC: Treatment options for patients ineligible for IO - patient case video
Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting
Просмотров 1533 месяца назад
Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting
Optimising the management of multiple myeloma in the early relapsed/refractory setting
Просмотров 16 тыс.3 месяца назад
Optimising the management of multiple myeloma in the early relapsed/refractory setting
GI CONNECT Update from ASCO 2024
Просмотров 4,6 тыс.3 месяца назад
GI CONNECT Update from ASCO 2024
Lung Cancer - Meeting Highlights from ASCO 2024
Просмотров 3,9 тыс.3 месяца назад
Lung Cancer - Meeting Highlights from ASCO 2024
Update from ASCO 2024
Просмотров 5644 месяца назад
Update from ASCO 2024
Regional differences in NET: Epidemiology, diagnosis, and referral strategies: Part 1
Просмотров 2,5 тыс.4 месяца назад
Regional differences in NET: Epidemiology, diagnosis, and referral strategies: Part 1

Комментарии

  • @HDMGuys786
    @HDMGuys786 4 дня назад

    Good

  • @MuzafarSajidi
    @MuzafarSajidi 6 дней назад

    Nice❤❤❤

  • @MuraliTharan-e3l
    @MuraliTharan-e3l 6 дней назад

    Pl Pp LpPlPp

  • @SkKumar-fo3st
    @SkKumar-fo3st 6 дней назад

    😊😅😮😮😮❤❤❤❤❤

  • @mancity903
    @mancity903 8 дней назад

    Shut up 🤫

  • @Ghu5ungn
    @Ghu5ungn 8 дней назад

    عندي مرض مناعي

  • @ozairabbas4646
    @ozairabbas4646 10 дней назад

    Good

  • @edwinteranblanco5504
    @edwinteranblanco5504 3 месяца назад

    😢😮

  • @rachidablkaide8769
    @rachidablkaide8769 3 месяца назад

    Hola

  • @christophersandmann
    @christophersandmann 4 месяца назад

    Thank you for all you do.

  • @aleksandrakowalczyk6043
    @aleksandrakowalczyk6043 6 месяцев назад

    Women. Women getting IUD.

  • @MilaWht
    @MilaWht 6 месяцев назад

    "Fear of pain amongst people getting IUDs" is because doctors often dismiss and downplay their pain giving just some ibuprofen cause they dont take their pain seriously

    • @brokenandcraked
      @brokenandcraked 6 месяцев назад

      I'm sure the men getting their IUD put in have their pain taken seriously

  • @brokenandcraked
    @brokenandcraked 6 месяцев назад

    Why did you say "people" considering an IUD? Last I checked, men don't have the parts needed to need an IUD. So, it should have been women considering an IUD.

    • @Pfluftl4326
      @Pfluftl4326 6 месяцев назад

      Last time I checked, women were still people. Also, trans men exist.

    • @brokenandcraked
      @brokenandcraked 6 месяцев назад

      @@Pfluftl4326 screw that. Stop erasing women from language. I'm tired of this misogyny.

    • @MilaWht
      @MilaWht 6 месяцев назад

      ​@@brokenandcrakeddon't pretend to not know and wonder what they meant when they said "people" like you don't know they're referring to trans people who have a uterus. Womp womp "trans men and intersex people exist so I'm going to be transphobic and get offended like the snowflake I am" lmao cope

    • @aleksandrakowalczyk6043
      @aleksandrakowalczyk6043 6 месяцев назад

      There's no such things as trans men getting IUD. And they're not women.

    • @sugoish9461
      @sugoish9461 5 месяцев назад

      ​@@brokenandcrakedTrans-inclusion is NOT erasure of women. I'm a cis woman and I am proud to support trans women.

  • @DCGreenZone
    @DCGreenZone 8 месяцев назад

    >>Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.<<

  • @CatFromFL
    @CatFromFL 9 месяцев назад

    It took me 9 cycles to completely eradicate my metastatic lesions in my bones. My first scans were mixed due to being off my soc x 4 months before starting Elacestrant. I scan every 90 days. And made many improvements every scan. It’s been my miracle- after 6.5 yrs on a soc prior.

  • @jstanbury61
    @jstanbury61 Год назад

    The slides are illegible

    • @cor2edtheheartofmedicaledu700
      @cor2edtheheartofmedicaledu700 Год назад

      Hello @jstanbury61, slides are available for download on our website and you can find them here: cor2ed.com/gu-connect/programmes/expert-knowledge-share-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice/ Thanks!

  • @heatherhoffman8128
    @heatherhoffman8128 Год назад

    😊

  • @JacksSparrow-ru9ni
    @JacksSparrow-ru9ni Год назад

    Hello

  • @hakanozduran2798
    @hakanozduran2798 Год назад

    VON WİLLİBRAND HEMOFİLİ A FACTOR 8 Type 2 b 😢😢😢😢😢😢😢😢

  • @elvinashourn4673
    @elvinashourn4673 2 года назад

    I’m so much excited about how dr OARE on RUclips channel was able to shrunk and cure my multiple fibroid and heavy period, thank you 🙏 very much xx dr OARE and you too can also visit him on RUclips channel for any compliant.